|20.79||-0.7100||-3.30%||Vol 6.28M||1Y Perf 42.08%|
|Sep 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||31.00||Analyst Rating||Strong Buy 1.16|
|Potential %||49.11||Finscreener Ranking||★★★★+ 57.64|
|Insiders Trans % 3/6/12 mo.||-100/-7/10||Value Ranking||★★★★ 54.88|
|Insiders Value % 3/6/12 mo.||-100/-80/-76||Growth Ranking||★★★★+ 63.63|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-70/-69||Income Ranking||— -|
|Price Range Ratio 52W %||91.19||Earnings Rating||Strong Sell|
|Market Cap||2.67B||Earnings Date||9th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Nov 2021|
|Estimated EPS Next Report||-0.31|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||5.10M|
|Avg. Monthly Volume||4.11M|
|Avg. Quarterly Volume||3.92M|
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 20.79 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 6.31M shares and market capitalization of 2.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.
The one-year performance of Aurinia Pharmaceuticals Inc stock is 42.08%, while year-to-date (YTD) performance is 50.33%. AUPH stock has a five-year performance of 909.22%. Its 52-week range is between 9.72 and 21.86, which gives AUPH stock a 52-week price range ratio of 91.19%
Aurinia Pharmaceuticals Inc currently has a PE ratio of -11.10, a price-to-book (PB) ratio of 5.11, a price-to-sale (PS) ratio of 46.66, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -42.30%, a ROC of -43.37% and a ROE of -50.50%. The company’s profit margin is -%, its EBITDA margin is -241.50%, and its revenue ttm is $57.59 Million , which makes it $0.45 revenue per share.
Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.31 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is 09th Nov 2021.
The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Strong Buy (1.16), with a target price of $31, which is +49.11% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aurinia Pharmaceuticals Inc has a Buy technical analysis rating based on Technical Indicators (ADX : 13.77, ATR14 : 1.26, CCI20 : 125.36, Chaikin Money Flow : 0.32, MACD : 1.79, Money Flow Index : 79.31, ROC : 17.46, RSI : 71.10, STOCH (14,3) : 83.71, STOCH RSI : 0.41, UO : 69.29, Williams %R : -16.29), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: George M. Milne (Buy at a value of $65 000), Jill D. Leversage (Buy at a value of $53 037), Joseph M. Miller (Buy at a value of $9 740), Matthew Donley (Buy at a value of $99 739), Michael Hayden (Option Excercise at a value of $550 100), Michael R. Martin (Option Excercise at a value of $60 400), Michael R. Martin (Sold 45 000 shares of value $754 625 ), Neil Solomons (Option Excercise at a value of $120 800), Neil Solomons (Sold 90 000 shares of value $1 340 200 ), R. Hector Mackay-Dunn (Buy at a value of $50 529), Robert Huizinga (Option Excercise at a value of $241 600), Robert Huizinga (Sold 5 000 shares of value $91 500 ), Stephen P. Robertson (Buy at a value of $14 526)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.